HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia.

Abstract
Recent cross-sectional and longitudinal studies indicate that measurements of peripheral blood carbonyl stress markers such as the advanced glycation end product (AGE) pentosidine and the reactive carbonyl-detoxifying B6 vitamin pyridoxal could be used as therapeutic biological markers in subpopulations of schizophrenia patients. Glyceraldehyde-derived AGEs (Glycer-AGE) have strong neurotoxicity, and soluble receptors for AGEs (sRAGE) may ameliorate the effects of AGEs. In the present study, we measured Glycer-AGEs and sRAGE levels to determine their potential as diagnostic, therapeutic, or clinical biological markers in patients with schizophrenia. After enrollment of 61 admitted Japanese patients with acute schizophrenia and 39 healthy volunteers, 54 patients were followed up from the acute stage to remission. Serum biomarkers were measured in blood samples taken before breakfast using competitive enzyme-linked immunosorbent assays, and Glycer-AGEs were significantly higher and sRAGE levels were significantly lower in patients with acute schizophrenia than in healthy controls. Glycer-AGEs/sRAGE ratios were also higher in schizophrenia patients and were stable during the clinical course. Furthermore, discriminant analyses confirmed that Glycer-AGEs and Glycer-AGEs/sRAGE ratios are significant diagnostic markers for schizophrenia, and distinguished between patients and healthy controls in 70.0% of cases. However, these markers of carbonyl stress were not correlated with clinical features, including disease severity, or with daily chlorpromazine doses. These data indicate the potential of Glycer-AGEs, RAGEs, and their relative ratios as diagnostic markers for patients with schizophrenia.
AuthorsMayu Takeda, Tohru Ohnuma, Masayoshi Takeuchi, Narimasa Katsuta, Hitoshi Maeshima, Yuto Takebayashi, Motoyuki Higa, Toru Nakamura, Shohei Nishimon, Takahiro Sannohe, Yuri Hotta, Ryo Hanzawa, Ryoko Higashiyama, Nobuto Shibata, Tomohito Gohda, Yusuke Suzuki, Sho-ichi Yamagishi, Yasuhiko Tomino, Heii Arai
JournalNeuroscience letters (Neurosci Lett) Vol. 593 Pg. 51-5 (Apr 23 2015) ISSN: 1872-7972 [Electronic] Ireland
PMID25766756 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Biomarkers
  • Glycation End Products, Advanced
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic
  • Glyceraldehyde
Topics
  • Adolescent
  • Adult
  • Aged
  • Biomarkers (blood)
  • Case-Control Studies
  • Female
  • Glycation End Products, Advanced (blood)
  • Glyceraldehyde (metabolism)
  • Humans
  • Male
  • Middle Aged
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic (blood)
  • Schizophrenia (blood, diagnosis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: